CAR T stands for chimeric antigen receptor T-cell. It refers to a type of cancer treatment in which a patient’s own immune cells (T-cells) are removed, genetically modified in a lab to recognize cancer, and then infused back into the body. The term “chimeric” means the receptor is artificially constructed from parts that don’t naturally occur together, combining fragments of lab-made antibodies with signaling components that activate the T-cell.
Breaking Down the Name
Each word in “chimeric antigen receptor” describes a specific part of what makes these engineered cells work.
Chimeric means made from mixed origins. The receptor on the surface of the T-cell is built from pieces of different proteins stitched together in a lab, creating something that doesn’t exist in nature. Think of it like a hybrid tool designed for a very specific job.
Antigen refers to the target. Antigens are proteins found on the surface of cells. Cancer cells carry certain antigens that the engineered receptor is designed to lock onto. The external portion of the CAR is built from antibody fragments chosen specifically for their ability to bind to a particular antigen on tumor cells.
Receptor describes the structure itself. It sits on the outside of the T-cell, acting as both a sensor and a trigger. When the external part grabs onto a cancer cell’s antigen, the internal part sends activation signals that tell the T-cell to multiply and attack. These internal signaling and co-stimulatory domains are what turn a simple binding event into a full immune response.
The “T-cell” part is the immune cell that carries this new receptor. T-cells are white blood cells your body already uses to fight infections and abnormal cells. CAR T therapy essentially upgrades them with better targeting equipment.
How the Treatment Works
The process starts with a blood draw called leukapheresis. A machine separates your white blood cells from the rest of your blood, then returns the remaining blood to your body. Those collected cells are shipped to a manufacturing facility where scientists insert a new gene into the T-cells, reprogramming them to produce the chimeric antigen receptor on their surface. This engineering and growing process typically takes three to six weeks.
During that waiting period, you may receive chemotherapy or radiation as “bridging therapy” to keep the cancer in check while your modified cells are being produced. Shortly before the infusion, you’ll undergo a round of chemotherapy specifically designed to suppress your existing immune cells so your body doesn’t reject the new ones.
The actual infusion is surprisingly quick: five to 30 minutes through an IV line. Once in your bloodstream, the CAR T-cells seek out cells carrying the target antigen, latch on, and begin destroying them. They also continue multiplying inside your body, building a larger army over time.
What CAR T Therapy Treats
Seven CAR T products are currently approved by the FDA, all for blood cancers. These include treatments sold under the names Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl. They’re used for various types of lymphoma, leukemia, and multiple myeloma, generally after other treatments have stopped working.
Patients are typically referred for CAR T therapy once their cancer is considered relapsed or refractory, meaning it has come back or hasn’t responded to standard treatments. Experts recommend referral as early as possible in that process rather than waiting through multiple additional rounds of conventional therapy. Factors like age, heart function, kidney function, and overall fitness are evaluated, but none of them automatically disqualify someone from being considered.
Side Effects to Know About
The most significant side effect is cytokine release syndrome, or CRS. When CAR T-cells activate in large numbers, they trigger a flood of immune signaling molecules that can cause fever, low blood pressure, difficulty breathing, and fatigue. In mild cases it feels like a bad flu. In severe cases it can affect organ function and require intensive care. CRS is expected and monitored closely, which is why patients stay near the treatment center for weeks after infusion.
A second major side effect involves the nervous system. Symptoms can start subtly with difficulty finding words or trouble concentrating, then progress to confusion, agitation, or in rare cases seizures. This neurological toxicity usually appears within the first two weeks and is reversible for most patients, but it requires close monitoring.
Cost and Access
CAR T therapy is one of the most expensive cancer treatments available. Medicare data from 2022 shows average costs around $499,000 for inpatient treatment and $413,000 for outpatient treatment. Those figures cover both the engineered cells and the surrounding medical care. Medicare does cover CAR T for eligible patients, and the therapy has become increasingly common in the Medicare population, particularly in inpatient settings.
A major limitation is the three-to-six-week manufacturing window. Because each treatment is custom-built from your own cells, there’s no way to start immediately. Researchers are developing “off-the-shelf” versions made from donor cells that could be ready within days. In one early trial, roughly 90% of patients received donor-derived CAR T-cells within five days of enrollment, cutting four to six weeks off the timeline. These allogeneic products are still in early clinical trials and not yet widely available.
Why It Doesn’t Yet Work for All Cancers
CAR T therapy’s success in blood cancers hasn’t translated easily to solid tumors like breast, lung, or colon cancer. The reasons are largely physical. Solid tumors create a hostile environment that blocks immune cells from getting in, strips away the chemical signals T-cells need to stay active, and surrounds itself with a dense matrix that acts like a wall. Tumors can also shed or change their surface antigens, making it harder for the CAR to find its target. Researchers are running trials against specific proteins found on solid tumors, but overcoming these barriers remains a significant challenge.